Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease

Contributed by: Business Wire

Logo

Tags

Biotechnology

FDA

Health

Pharmaceutical

Oncology

Other Science

Mental Health

Research

Managed Care

Hospitals

Genetics

Science

Clinical Trials

Cardiology

Prothena Corporation plc

More Like This

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

PR Newswire associated0

Alamar Biosciences and ALZpath, Inc. Announce Strategic Supply Agreement for pTau217 Antibody to Advance Alzheimer's Disease Research

Professor Claude Wischik (Photo: Business Wire)

TauRx to Present Two-Year Data from Phase III Trial of HMTM in Alzheimer’s Disease at the AD/PD™ 2024 Conference in March

Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy